Effectiveness of antimalarial drugs.
Baird
J Kevin
JK
U.S. Naval Medical Research Unit No. 2, Jakarta, Indonesia. baird@namru2.org
D000818:Animals; D000962:Antimalarials / Q000009:adverse effects / Q000627:therapeutic use*; D002738:Chloroquine / Q000627:therapeutic use; D004338:Drug Combinations; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D008018:Life Cycle Stages; D008288:Malaria / Q000188:drug therapy* / Q000517:prevention & control; D015767:Mefloquine / Q000627:therapeutic use; D010349:Patient Compliance; D010961:Plasmodium / Q000187:drug effects / Q000254:growth & development; D011319:Primaquine / Q000627:therapeutic use; D011739:Pyrimethamine / Q000627:therapeutic use; D011803:Quinine / Q000627:therapeutic use; D055502:Secondary Prevention; D013413:Sulfadoxine / Q000627:therapeutic use; D017211:Treatment Failure
D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011803:Quinine; D011319:Primaquine; D015767:Mefloquine; D011739:Pyrimethamine